Nanoencapsulated Quercetin countervails doxorubicin induced cardio and liver toxicity in rats
Gregory Marslin, Jose Prakash
Sathyabama Institute of Science and Technology
Abstract: Doxorubicin is the potent anthracycline antibiotic used in cancer treatment for several years. However, the clinical utility of this drug as a chemotherapeutic agent is limited due to the induction of cardiac toxicity. In order to overcome this issue, we have evaluated the potential of quercetin nanoparticles to countervail doxorubicin induced cardiac toxicity in rats. Querctin loaded PLGA nanoparticles of 190-210 nm size with an encapsulation efficiency of 72% was used in this study. Rats weighing about 250-300 g were divided into four groups (1, 2, 3 and 4) each with 6 adult females. Group 1 received normal saline and treated as control. Group 2, 3 and 4 received 5 mg/kg doxorubicin once in 5 days via intraperitoneal injection over the period of 15 days (15 mg/kg cumulative dose). Group 3 and 4 respectively received 50mg/ kg free quercetin and its equivalent nano form, in addition to doxorubicin. On day 16, blood samples were collected from orbital sinus of each animal for biochemical analysis. Hearts were collected after dissection and tissues were analyzed for gross pathological changes. Significant biochemical, hematological and hisopatholgical changes were noted in animals treated with doxorubicin either alone or in combination with free quercetin. Nevertheless, animals administered with nanoencapsulated quercetin and doxorubicin did not show any symptom of cardiac toxicity. Overall, our results conclude Quercetin delivery as nanoparticles protect doxorubicin induced cardiac toxicity.